Dr. Senderowicz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9406 Linden Ave
Bethesda, MD 20814Phone+1 301-530-0892
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1990 - 1992
New York-Presbyterian/QueensInternship, Internal Medicine, 1989 - 1990
University of Buenos AiresClass of 1987
Certifications & Licensure
NY State Medical License 1992 - 2025
Publications & Presentations
PubMed
- 14 citationsA Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.Kristie A Blum, Jeffrey G Supko, Michael B Maris, Ian W Flinn, Andre Goy
Cancer Research Communications. 2022-08-01 - 20 citationsPaediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with p...Andrew D.J. Pearson, Kimberly Stegmaier, Franck Bourdeaut, Gregory H. Reaman, Delphine Heenen
European Journal of Cancer. 2020-11-01 - 46 citationsA randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.Martin H. Voss, Arif Hussain, Nicholas J. Vogelzang, J.-L. Lee, Bhumsuk Keam
Annals of Oncology. 2017-11-01
Abstracts/Posters
- Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor...Adrian Senderowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or...Adrian Senderowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
New Compounds Targeting Epigenetics Show Promise in Lymphoma PatientsMarch 5th, 2018
Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 in Combination with Checkpoint InhibitorsJanuary 16th, 2018- Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate CancerDecember 12th, 2017
- Join now to see all
Grant Support
- Translational Effects Of Small Molecule Cell Cycle ModulNational Institute Of Dental &Craniofacial Research2003–2004
- Antiproliferative Effects Of Small Molecules: Basic AndNational Institute Of Dental &Craniofacial Research2002–2004
- Antiproliferative Effects Of Small MoleculesNational Institute Of Dental &Craniofacial Research2000–2003
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
